Other Events ·
Teva Pharmaceutical Industries Ltd. executed an amendment to its deposit agreement to terminate its American…
TEVATeva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. executed an amendment to its deposit agreement to terminate its American Depositary Share (ADS) program and list its ordinary shares directly on the New York Stock Exchange. The amendment establishes a mandatory exchange mechanism where each ADS converts into one ordinary share. This termination is scheduled for September 14, 2026, at the open of business in New York, after which all outstanding ADSs will be cancelled and replaced by economically equivalent NYSE-listed ordinary shares. Teva Pharmaceutical Industries Ltd. operates in the pharmaceutical industry, developing, manufacturing, and marketing generic and specialty medicines.